USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 11, 2022 | Jun 2022 | $-0.83 | $-0.74 | $-0.83 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 11, 2022 | Jun 2022 | $0.00 | - | $0.00 |
Akero Therapeutics's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 5 | $-0.83 | $-1.02 | $-0.71 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 6 | $-3.42 | $-3.59 | $-2.95 |
| Dec 2023 | 6 | $-3.72 | $-4.16 | $-3.22 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 0 / 0 | $-0.83 | $-0.82 | $-0.82 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-3.42 | $-3.26 | $-3.26 |
| Dec 2023 | 0 / 0 | $-3.72 | $-3.48 | $-3.48 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 3 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 5 | $0.00 | $0.00 | $0.00 |
| Dec 2023 | 5 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 6, 2022 | Mar 2022 | $-0.80 | $-0.74 | 7.50% |
| Feb 25, 2022 | Dec 2021 | $-0.82 | $-0.93 | -13.41% |
| Nov 12, 2021 | Sep 2021 | $-0.91 | $-0.70 | 22.81% |
| Aug 13, 2021 | Jun 2021 | $-0.71 | $-0.83 | -17.61% |
| May 13, 2021 | Mar 2021 | $-0.94 | $-0.43 | 54.06% |
| Mar 16, 2021 | Dec 2020 | $-0.60 | $-0.86 | -44.42% |
| Nov 12, 2020 | Sep 2020 | $-0.67 | $-0.63 | 6.11% |
| Aug 12, 2020 | Jun 2020 | $-0.62 | $-0.57 | 7.72% |
| May 13, 2020 | Mar 2020 | $-0.61 | $-0.42 | 31.15% |
| Mar 16, 2020 | Dec 2019 | $-0.58 | $-0.55 | 5.97% |
| Nov 12, 2019 | Sep 2019 | $-0.43 | $-0.56 | -30.69% |
| Aug 12, 2019 | Jun 2019 | $-0.36 | $-0.26 | 28.51% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 25, 2022 | Dec 2021 | $-2.77 | $-2.89 | - |
| Mar 16, 2021 | Dec 2020 | $-2.21 | $-2.48 | - |
| Mar 16, 2020 | Dec 2019 | $-2.81 | $-1.37 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 6, 2022 | Mar 2022 | $0.00 | - | - |
| Feb 25, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Nov 12, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 13, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 13, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 12, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 13, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 16, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 12, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 12, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 25, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 16, 2020 | Dec 2019 | $0.00 | $0.00 | - |
AKRO's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Akero Therapeutics's next quarterly earnings is $-0.83, with a low EPS estimation of $-1.02, and a high estimation of $-0.71.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.83, the last 2 month trend is $-0.82, and the 3 month trend is $-0.82.
Based on analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Akero Therapeutics's previous earnings date was May 6, 2022 for its fiscal quarter ended Mar 31, 2022.
AKRO's earnings per share (EPS) was $-0.74, beating the consensus analysts forecast of $-0.80 by 7.50%.
The EPS was higher than the previous fiscal quarter (Dec 2021) by -20.43%, and lower than the same period a year before (Mar 2021) by 72.09%.
The company reported a net income of $-26.03M.Free cash flow for the quarter was $-22.88M , compared to $-26.70M last quarter and $-18.35M a year before.
AKRO ended the quarter with $1.25M in total debt, a decrease of -17.22% compared to the previous quarter, and a decrease of -30.43% compared to the same quarter a year before.
Akero Therapeutics's previous annual earnings date was Feb 25, 2022 for its fiscal year ended Dec 31, 2021.
AKRO's earnings per share (EPS) was $-2.89, missing the consensus analysts forecast of $-2.77 by 4.33% , and lower than the previous year's EPS (Dec 2020) by 16.53%.
Revenues were $0.00.
The company reported a net income of $-100.78M.
Akero Therapeutics reported a free cash flow of $-79.68M for its fiscal year, compared to $-70.95M a year ago.
The company ended the fiscal year with $1.52M in total debt, a decrease of -16.24% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
